Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for ...

Vertiv Holdings ( NYSE: VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...

William Blair cheers Tesla-Samsung chip deal but keeps TSLA at Hold, citing auto margin woes and valuation concerns.

Exelixis Q2 revenue missed estimates, but strong Cabometyx sales lifted earnings. STELLAR trial delays and strategy shifts ...

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

Palo Alto Networks, Inc. (NASDAQ:PANW) is one of the best long term low volatility stocks to buy now. On July 16, William ...

CoStar’s second quarter saw solid execution, with revenue and non-GAAP earnings both surpassing Wall Street expectations, ...

Fintel reports that on July 22, 2025, William Blair upgraded their outlook for Booz Allen Hamilton Holding (NYSE:BAH) from ...

Executives at the laboratory companies said they expect the effects on testing services from the Republicans’ tax and ...

Sarepta Therapeutics shares jumped over 36% on Tuesday after the company said it had received FDA approval to restart ...

(Reuters) -Sarepta Therapeutics shares snapped a three-day losing streak on Tuesday, as analysts said resumption of U.S. shipments for its muscular gene therapy soothes immediate concerns about ...

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...